Vocal Tics Guide for Sounds Words and Misunderstood Symptoms

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

Vocal tics are repeated sounds made through the voice, throat, nose or breathing muscles. You may hear throat clearing, sniffing, coughing, grunting, humming, syllables, words or short phrases that feel hard to stop. Vocal tics can happen alone in persistent vocal tic disorder, or they can appear with motor tics in Tourette syndrome. The Centers for Disease Control and Prevention (CDC) describes vocal tics as sounds a person makes with the voice, including humming, clearing the throat or yelling out a word or phrase.

Sounds, words and repeated vocal patterns

Vocal tics can be simple or complex. Simple vocal tics are short sounds. Complex vocal tics may include words, phrases or repeated speech patterns.

Simple vocal tics may include the following.

  • Throat clearing
  • Sniffing
  • Coughing
  • Grunting
  • Humming
  • Clicking
  • Squeaking
  • Short sounds or syllables

Complex vocal tics may include repeated words, short phrases, repeating your own words or repeating words said by another person. The National Institute of Neurological Disorders and Stroke (NINDS) describes Tourette syndrome as a neurological disorder that can cause sudden unwanted repeated movements or vocal sounds called tics.

A vocal tic can be quiet or loud. It can happen once in a while or many times a day. It can appear during class, meetings, reading, rest, stress, excitement or fatigue. Some people can delay a vocal tic for a short period. That delay can take effort and may lead to more symptoms later.

A vocal tic can be misunderstood because it happens in social settings. A throat clearing tic may be treated as rudeness. A humming tic may be treated as distraction. A word tic may be judged as intentional speech. Calm education can reduce blame.

Throat clearing and coughing patterns

Throat clearing and coughing are common vocal tic patterns. They can be mistaken for allergies, asthma, reflux, colds or throat irritation. Those health issues can also cause throat symptoms, so a clinician may need to review the pattern.

A throat clearing tic may happen repeatedly across days or weeks. It may increase during quiet settings, school tasks or stress. It may happen even when there is no infection or mucus. A child may be corrected often because the sound interrupts class.

A coughing tic can also be confusing. It may sound like a respiratory symptom, but the pattern may be sudden, repeated and linked to an urge. The person may feel pressure or discomfort before the sound and brief relief afterward.

You should seek medical review when coughing, throat clearing or sniffing is new, persistent, severe, painful, linked with breathing problems, fever, wheezing, swallowing problems or blood. A clinician can review medical causes and tic patterns.

Vocal tics compared with speech habits

Vocal tics can look similar to speech habits, but the inner experience is often different. A tic may feel sudden and hard to hold back. It may come with a physical urge, throat sensation or pressure that eases after the sound.

A speech habit may be more tied to routine, filler words or learned speaking patterns. It may be easier to change once a person notices it. A vocal tic often resists simple reminders to stop.

Repeated correction can make vocal tics harder to live with. A child who is told to be quiet all day may feel embarrassed or anxious. An adult who tries to hide every sound may feel drained after meetings or social events.

You do not need to decide alone. A clinician can ask about age of onset, symptom duration, motor tics, vocal patterns, urge sensations, medication exposure, stress, sleep and related conditions.

Coprolalia as a rare vocal tic

Coprolalia means involuntary swearing or socially inappropriate words. It is one of the most publicized Tourette symptoms, but most people with Tourette syndrome do not have it. CDC states that media often show Tourette syndrome through coprolalia or echolalia, while these symptoms are rare and are not required for diagnosis.

This misconception creates stigma. A person without coprolalia may have real Tourette symptoms and still be doubted because their tics do not match the public stereotype. A person with coprolalia may be judged as rude or hateful when the words are part of an involuntary tic.

Coprolalia can be highly distressing for the person who has it. The words may conflict with their values. They may fear public settings, school discipline, workplace reactions or social rejection.

Support should be practical. A child may need a school plan. A teen may need privacy and anti bullying support. An adult may need workplace planning or a short explanation for public situations. Severe or socially harmful vocal tics should be reviewed with a qualified clinician.

School and public settings

Vocal tics can create problems in classrooms because schools often expect quiet. A student may clear the throat, hum, cough, sniff or repeat a sound during lessons or tests. If staff do not know about tic disorders, the student may be corrected or punished.

School support should fit the symptom pattern. A child with vocal tics may need a quiet test space, permission for brief breaks, a water bottle, a discreet signal with the teacher or staff education. The plan should also address teasing, copying, filming or discipline tied to tic symptoms.

CDC notes that Tourette syndrome can affect school because tics may distract a child, make reading or writing hard and expose the child to teasing or bullying.

Public settings can also be hard. Vocal tics may draw attention in stores, religious settings, public transport, theaters, meetings or waiting rooms. A short prepared line can help. You might say, “I have a tic disorder. That sound is involuntary.” You do not owe strangers a long medical explanation.

For children, a parent or caregiver can answer calmly. For teens and adults, privacy matters. You can choose when an explanation helps and when leaving the setting is the better option.

Vocal tics in children

Vocal tics in children may start as sniffing, throat clearing, humming or small sounds. These can appear after motor tics or around the same general period. CDC states that Tourette syndrome symptoms often begin between ages 5 and 10.

If your child has vocal tics, avoid repeated commands to stop. A child may suppress a tic briefly, but that effort can be tiring. Holding back symptoms at school can also lead to more symptoms at home.

Ask about pain, embarrassment, teasing and school trouble. A child may not explain the urge clearly. They may only say the sound “has to come out.” Keep the conversation calm and brief.

A care visit may help if vocal tics last, cause stress, affect school, appear with motor tics or create social problems. Mention any eye blinking, shoulder movements, head jerks or other motor tics because that affects diagnosis.

Vocal tics in adults

Adults with vocal tics may have had symptoms since childhood. Some were diagnosed early. Others were treated for allergies, anxiety or habits for years before tic disorder was considered.

Vocal tics can affect meetings, calls, presentations, shared offices, public roles and relationships. A throat clearing tic may interrupt quiet work. A word tic may create fear around public speaking. A humming tic may draw attention during meetings.

Work support may include brief breaks, written follow up after calls, camera flexibility during virtual meetings, a private space during tic flares or a short disclosure to people who need to know. A clinician can help document support needs if formal accommodations are needed.

Adults should also review related conditions. ADHD, OCD, anxiety, mood concerns, sleep issues and pain can affect daily life with vocal tics. Treating related symptoms can make the full care plan more useful.

Care visit preparation

A care visit for vocal tics should include clear examples. Tics may not appear during a short appointment, so notes can help.

Bring information about the following.

  • First age or date when vocal tics appeared
  • Main sounds, words or phrases
  • Motor tics if present
  • How long symptoms have lasted
  • School, work or social effects
  • Pain, throat irritation or fatigue
  • Stress, sleep or illness patterns
  • Related ADHD, OCD or anxiety symptoms
  • Medication or substance changes
  • Safety or self injury concerns

A short video may help if the person with tics agrees. Ask before recording, especially with teens and adults. Respect privacy.

The diagnosis depends on tic type, duration and age of onset. Tourette syndrome requires both motor and vocal tics that have been present for at least one year, with onset before age 18. Persistent vocal tic disorder may be diagnosed when vocal tics last at least one year without motor tics. Provisional tic disorder may apply when symptoms have lasted less than one year. CDC outlines these diagnostic categories for tic disorders.

Treatment and support options

Treatment depends on impact. Mild vocal tics may need education and monitoring only. Vocal tics that cause pain, school issues, work limits, social distress or major stress may need active support.

CBIT is a behavioral treatment for tics. CDC describes CBIT as a planned behavioral therapy that helps a person become aware of tics and learn responses that can reduce symptoms.

Medication may be considered when vocal tics are severe, painful, socially harmful or disruptive. Medication choices require clinical guidance because benefits, side effects and monitoring needs vary.

Support may also include school accommodations, workplace changes, therapy for anxiety, care for OCD, ADHD treatment or family education. A useful plan should reflect the settings where vocal tics create the most difficulty.

Research context

Tic research continues to study genetics, brain circuits, behavioral treatment, medication safety, school support and related conditions. Better research can help clinicians match care to symptom patterns.

Regulated psychedelic research has also added useful scientific work on brain networks, emotion processing and therapeutic models. Psilocybin is not an established treatment for vocal tics, Tourette syndrome or tic disorders. Any future research in this area would need careful diagnosis, validated tic measures, long term safety review and attention to ADHD, OCD and anxiety.

Links to symptoms and treatment

If you are comparing vocal tics with movement symptoms, read a motor tics guide. Motor tics include repeated blinking, facial movements, shoulder shrugging, head jerking, touching, tapping or body movements.

If you want the broader symptom picture, read a Tourette syndrome symptoms guide. That page should explain motor tics, vocal tics, simple tics, complex tics, premonitory urges and changes over time.

If vocal tics are affecting daily life, read a Tourette syndrome treatment guide. That page should cover CBIT, medication, related conditions, school support, adult care and questions to ask a clinician.

If symptoms are new or you do not know the diagnosis, read a tic disorder guide. That page should compare Tourette syndrome, persistent vocal tic disorder, persistent motor tic disorder and provisional tic disorder.

Research note

As you review vocal tics, Tourette symptoms and future research questions, we at Rose Hill Life Sciences approach this topic through science led education. Our work focuses on psychedelic research, production and study of Psilocybe cubensis, the intersection of science and therapeutic integration and our Massachusetts research work, while vocal tic diagnosis and treatment decisions should remain with qualified healthcare professionals.

Conclusion

If you notice repeated sounds, write down what the sounds are, when they began, how long they have lasted and how they affect daily life. Include any motor tics, such as blinking, shoulder movements, facial movements or head jerks.

If the vocal tics are mild and do not disrupt life, ask a clinician about monitoring. If they cause school problems, work limits, social stress, pain, throat irritation or distress, ask about a fuller tic disorder evaluation.

If the vocal tic includes words, phrases or socially sensitive language, seek support early. A practical plan can protect dignity, reduce conflict and help others respond more accurately.

Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.